Search | OpenScholar

Search results

356 results found

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson’s disease. Movement Disorders 2002;17:961-968.

Publication: Journal Article

Hauser, RA, and NH Holford. 2002. “Quantitative Description of Loss of Clinical Benefit Following Withdrawal of Levodopa-Carbidopa and Bromocriptine in Early Parkinson’s Disease. Movement Disorders 2002;17:961-968.”. Movement Disorders.

Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Movement Disorders 1994;9:467-469.

Publication: Journal Article

Hauser, RA, and R Trehan. 1994. “Initial Experience With Electroconvulsive Therapy for Progressive Supranuclear Palsy. Movement Disorders 1994;9:467-469.”. Movement Disorders.

The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708.

Publication: Journal Article

Woodward, WR, CW Olanow, RM Beckner, RA Hauser, LL Gauger, JM Cedarbaum, and J Nutt. 1993. “The Effect of L-Dopa Infusions With and Without Phenylalanine Challenges in Parkinsonian Patients: Plasma and Ventricular CSF L-Dopa Levels and Clinical Responses. Neurology 1993;43:1704-1708.”. Neurology.

Effective Parkinson’s treatment. An update on strategy. Senior patient. 1990;2:26-31.

Publication: Journal Article

Hauser, RA, and CW Olanow. 1990. “Effective Parkinson’s Treatment. An Update on Strategy. Senior Patient. 1990;2:26-31.”. Senior Patient.

Tolcapone and hepatotoxic effects. Arch Neurol 2000:57; 263-267.

Publication: Journal Article

Olanow, CW, and Tasmar Advisory Panel. 2000. “Tolcapone and Hepatotoxic Effects. Arch Neurol 2000:57; 263-267.”. Arch Neurol.

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders 2000;15:485-489.

Publication: Journal Article

Hauser, RA, WC Koller, JP Hubble, T Malapira, K Busenbark, and WC Olanow. 2000. “Time Course of Loss of Clinical Benefit Following Withdrawal of Levodopa/Carbidopa and Bromocriptine in Early Parkinson’s Disease. Movement Disorders 2000;15:485-489.”. Movement Disorders.

Pramipexole-induced somnolence and episodes of daytime sleep. Movement Disorders 2000;15:658-663.

Publication: Journal Article

Hauser, RA, L Gauger, WM Anderson, and TA Zesiewicz. 2000. “Pramipexole-Induced Somnolence and Episodes of Daytime Sleep. Movement Disorders 2000;15:658-663.”. Movement Disorders.

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson’s disease. Arch Neurol 1999;56:179-187.

Publication: Journal Article

Hauser, RA. 1999. “Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson’s Disease. Arch Neurol 1999;56:179-187.”. Arch Neurol.

Use of placebo surgery in controlled trials of cellular-based therapy for Parkinson’s disease. NEJM 1999; 341:988-992.

Publication: Journal Article

Freeman, TB, DE Vawter, PE Leaverton, JH Godbold, RA Hauser, CG Goetz, and CW Olanow. 1999. “Use of Placebo Surgery in Controlled Trials of Cellular-Based Therapy for Parkinson’s Disease. NEJM 1999; 341:988-992.”. NEJM.

Neurosurgery for Parkinson's Disease. Seminars in Neurology 2001; 21:91-101.

Publication: Journal Article

Zesiewicz, TA, and RA Hauser. 2001. “Neurosurgery for Parkinson’s Disease. Seminars in Neurology 2001; 21:91-101.”. Seminars in Neurology.